JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer
Yuksel, Ozgur Haki; Urkmez, Ahmet; Akan, Serkan; Yldirim, Caglar; Verit, Ayhan;
  PDF(new window)
 Abstract
Purpose: To predict prostatic carcinoma using a logistic regression model on prebiopsy peripheral blood samples. Materials and Methods: Data of a total of 873 patients who consulted Urology Outpatient Clinics of Fatih Sultan Mehmet Training and Research Hospital between February 2008 and April 2014 scheduled for prostate biopsy were screened retrospectively. PSA levels, prostate volumes, prebiopsy whole blood cell counts, neutrophil and platelet counts, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), biopsy results and Gleason scores in patients who had established diagnosis of prostate cancer (PCa) were evaluated. Results: This study was performed on a total of 873 cases, with an age range 48-76 years, divided into three groups as for biopsy results. with diagnoses of benign prostatic hyperplasia (BPH) (n
 Keywords
Prostatic carcinoma;PSA;platelet-to-lymphocyte ratio;neutrophil-to-lymphocyte ratio;
 Language
English
 Cited by
1.
Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy, BMC Cancer, 2016, 16, 1  crossref(new windwow)
2.
Predictive value of neutrophil-to-lymphocyte ratio in diagnosis of prostate cancer among men who underwent template-guided prostate biopsy, Medicine, 2016, 95, 44, e5307  crossref(new windwow)
3.
Clinical implications of pretreatment inflammatory biomarkers as independent prognostic indicators in prostate cancer, Journal of Clinical Laboratory Analysis, 2017, 08878013, e22277  crossref(new windwow)
 References
1.
Fujita K, Hosomi M, Nakagawa M, et al (2014). White blood cell count is positively associated with benign prostatic hyperplasia. Int J Urol, 21, 308-2. crossref(new window)

2.
Fujita K, Imamura R, Tanigawa G, et al (2012). Low serum neutrophil count predicts a positive prostate biopsy. Prostate Cancer Prostatic Dis, 15, 386-0. crossref(new window)

3.
Gorelick C, Andikyan V, Mack M, Lee YC, Abulafia (2009). Prognostic significance of preoperative thrombocytosis in patients with endometrial carcinoma in an innercity population. Int J Gynecol Cancer, 19, 1384-9. crossref(new window)

4.
Gueron G, De Siervi A, Vazquez E (2012). Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior. Prostate Cancer Prostatic Dis, 15, 213-1 crossref(new window)

5.
Gungor T, Kanat-Pektas M, Sucak A, Mollamahmutoglu L (2009). The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Arch Gynecol Obstet, 279, 53-6. crossref(new window)

6.
Jarnicki A, Putoczki T, Ernst M (2010). Stat3: linking inflammation to epithelial cancer more than a "gut" feeling? Cell Div, 5, 14. crossref(new window)

7.
Kantoff PW, Higano CS, Shore ND, et al (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 363, 411-2. crossref(new window)

8.
Karazanashvili G (2008). Editorial comment on: the relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol, 54, 1383-4. crossref(new window)

9.
Keizman D, Gottfried M, Ish-Shalom M, et al (2012). Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistantprostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist, 17, 1508-4. crossref(new window)

10.
Kerpsack JT, Finan MA (2000). Thrombocytosis as a predictor of malignancy in women with a pelvic mass. J Reprod Med, 45, 929-2.

11.
Kramer G, Mitteregger D, Marberger M (2007). Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol, 51, 1202-6. crossref(new window)

12.
Li AJ, Madden AC, Cass I, et al (2004). The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol, 92, 211-4. crossref(new window)

13.
Mantovani A, Allavena P, Sica A, Balkwill F (2008). Cancerrelated inflammation. Nature, 454, 436-4. crossref(new window)

14.
McDonald AC, Vira MA, Vidal AC, et al (2014). Association between systemic inflammatory markers and serum prostatespecific antigen in men without prostatic disease - the 2001-2008 national health and nutrition examination survey. Prostate, 74, 561-7. crossref(new window)

15.
Mengus C, Le Magnen C, Trella E, et al (2011). Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. J Transl Med, 9, 162. crossref(new window)

16.
Mistry K, Cable G (2003). Meta-analysis of prostatespecific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract, 16, 95-1. crossref(new window)

17.
Nuhn P, Vaghasia AM, Goyal J, et al (2013). Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castrationresistantprostate cancer (mCRPC) treated with first-line docetaxel. BJU Int, e-pub ahead of print, doi: 10.1111/bju.12531. crossref(new window)

18.
Palapattu GS, Sutcliffe S, Bastian PJ, et al (2005). Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis, 26, 1170-1.

19.
Pond GR, Armstrong AJ, Wood BA, et al (2012). Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. BJU Int, 110, 461-8. crossref(new window)

20.
Prins RC, Rademacher BL, Mongoue-Tchokote S, et al (2012). C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol, 30, 33-7. crossref(new window)

21.
Roehl KA, Antenor JA, Catalona WJ (2002). Serial biopsy results in prostate cancer screening study. J Urol, 167, 2435-9. crossref(new window)

22.
Schaider H, Oka M, Bogenrieder T, et al (2003). Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer, 103, 335-3. crossref(new window)

23.
Shafique K, Proctor MJ, McMillan DC, et al (2012). Systemic inflammation and survival of patients with prostate cancer: evidence from the glasgow inflammation outcome study. Prostate Cancer Prostatic Dis, 15, 195-1. crossref(new window)

24.
Shafique K, Proctor MJ, McMillan DC, et al (2013). The modified glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients. BMC Cancer, 13, 292. crossref(new window)

25.
Sonpavde G, Pond GR, Armstrong AJ, et al (2014). Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer, 12, 317-4. crossref(new window)

26.
Sumbul AT, Sezer A, Abali H, et al (2014). Neutrophil-tolymphocyte ratio predicts PSA response, but notoutcomes in patients with castration-resistant prostate cancer treated withdocetaxel. Int Urol Nephrol, 46, 1531-5. crossref(new window)

27.
Tai CG, Johnson TV, Abbasi A, et al (2014). External validation of the modified glasgow prognostic score for renal cancer. Indian J Urol, 30, 33-7. crossref(new window)

28.
Tanik S, Albayrak S, Zengin K, et al (2014). Is the neutrophillymphocyte ratio an indicator of progression in patients with benign prostatic hyperplasia? Asian Pac J Cancer Prev, 15, 6375-9. crossref(new window)

29.
Templeton AJ, Pezaro C, Omlin A, et al (2014). Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer, 120, 3346-2. crossref(new window)